Рет қаралды 10,302
Juan Pablo Frías explains the significance of the SURPASS-2 findings, in which the dual agonist tirzepatide provided superior glycemic control and weight loss to semaglutide (5:44).
View more on Medicine Matters diabetes: bit.ly/3gRSoyi